RVPH

Reviva is a late-stage but pre-revenue clinical biotech whose entire equity value rests on one advanced candidate, brilaroxazine, for schizophrenia and adjacent CNS indications. The 10-K is explicit: the company has 'never generated any product revenues,' expects 'significant losses for the foreseeable future,' and its 'recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.' Five straight years of net losses (-$8.5M, -$28.3M, -$39.3M, -$29.9M, -$19.9M) with zero revenue confirm this is a cash-burn story, not a business yet. Accumulated deficit sits at -$184M against just $8.65M of equity — ROE is a meaningless -230%.

The balance sheet is the disqualifier. Cash of $14.4M against operating cash burn of -$24.6M implies well under a year of runway at the current pace, which is exactly why management is diluting aggressively: a $50M ATM program (150,800 shares sold for $1.5M in 2025, another 570,845 for $2.5M in early 2026) plus a March 2026 public offering. The 1-for-20 reverse split effective March 2026 — which collapsed shares outstanding to 12.8M — is a Nasdaq-listing survival maneuver, not a sign of health, and the stock still trades at $0.66. The filing also discloses identified material weaknesses in internal control over financial reporting as of December 31, 2025, warning of possible restatement, and flags warrant liabilities that can swing reported results.